Assess whether a CMC change is a comparability or a new product (0466bf)

Situation

In an RWE group proposing a post-marketing study instead of a new RCT, advisory-committee question list that exposes a weak secondary endpoint is the evidence after an AdCom briefing document that overstates subgroup findings. Labeling negotiator has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences Clinical and Evidence Strategy close using advisory-committee question list that exposes a weak secondary endpoint.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Authorize A CMC change is a comparability now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after an AdCom briefing document that overstates subgroup findings.
• Keep A new product in force until advisory-committee question list that exposes a weak secondary endpoint is completed after an AdCom briefing document that overstates subgroup findings for labeling negotiator.
• Treat advisory-committee question list that exposes a weak secondary endpoint as A CMC change is a comparability because both readings appear after an AdCom briefing document that overstates subgroup findings.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page a CMC change is turns on in advisory-committee question list that exposes a weak secondary endpoint.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against an AdCom briefing document that overstates subgroup findings and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation